Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 4Carcinoma, Transitional Cell 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Urothelial Cancer 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 11pembrolizumab 10Paclitaxel 10Fluorouracil 9Oxaliplatin 8Radiotherapy 7Nivolumab 7Leucovorin 6Cisplatin 6Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Taxes 4durvalumab 3Trastuzumab 3Capecitabine 3relatlimab 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2Radiation 2Proton Therapy 2Practice Guidelines as Topic 2Irinotecan 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 2Drug Therapy 2Docetaxel 2Cetuximab 2Blood Specimen Collection 2zimberelimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Esophageal Neoplasms × enfortumab vedotin × Clear all
NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Astellas Pharma Inc

Phase 2 Active not recruiting
329 enrolled 23 charts
BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡